Here are the DEF 14A proxy statements from Dare Bioscience, Inc. (DARE) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow DARE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DARE filings page.
Daré Bioscience, Inc. (DARE) is asking stockholders to approve the potential future issuance of up to 8,934,345 common shares upon exercise of warrants issued in its August 2026 financing. The special meeting is scheduled for November 10, 2026; a second proposal would authorize an adjournment, if needed, to solicit votes for the warrant proposal. The board recommends voting “FOR” both proposals.
If approved, the warrants become exercisable, but holders are not required to exercise them. Assuming full exercise and cash payment, Daré would issue 8,934,345 shares—approximately 45.4% of its common shares outstanding on September 30, 2026—and receive approximately $12.4 million in gross proceeds. Exercise is subject to a 4.99% beneficial ownership limit, or 9.99% for holders electing that limit. The common warrants have a $1.37 exercise price; placement agent warrants have a $2.1235 exercise price. Daré had 19,669,083 common shares outstanding as of September 30, 2026.
Daré Bioscience is asking stockholders to vote at its virtual 2026 annual meeting on June 11, 2026. Holders of 14,559,502 shares of common stock as of April 14, 2026 may attend and vote online.
Key items include electing two Class III directors, ratifying Haskell & White LLP as auditor, and advisory votes on executive pay and how often that say‑on‑pay vote should occur. Stockholders are also asked to approve a potential future issuance of common stock to Lincoln Park Capital Fund, LLC under Nasdaq rules, and to amend the 2022 Stock Incentive Plan to add 1,500,000 shares for equity awards.
The proxy details board composition, governance practices, ownership, and 2025 executive pay. In 2025, CEO Sabrina Martucci Johnson received total compensation of $801,081 and Chief Accounting Officer MarDee Haring‑Layton received $546,858, largely driven by salary and stock option grants.